Share Buyback

With a promising brain injury drug and no approved rivals, Oragenics heads to a tax-haven investor summit to secure funding for its next critical phase.

Propanc Biopharma is taking a 100-year-old cancer treatment concept into modern human trials, targeting advanced tumors and expanding into fibrosis.

Investors and HR leaders watch as Unum prepares to release its Q4 results and 2026 strategy in a rapidly evolving workplace benefits landscape.

Erasca reports promising early data for its pan-RAS inhibitor, ERAS-0015, showing tumor shrinkage at low doses and shaking up the competitive landscape.

EfTEN Real Estate Fund reports its best-ever operating results, proposing an 8% dividend hike, while a minor portfolio revaluation hints at market shifts.

Hong Kong's 3E Network completes a $2M financing round, fueling its strategic shift into the competitive global AI infrastructure market.

EpicQuest Education's CES award highlights its AI university plans, but a closer look reveals a complex picture of innovation, market hype, and financial risk.

With up to $80.8M in new funding, Curis is set to accelerate trials for emavusertib, a promising drug targeting some of the toughest blood cancers.

Operational failures at a key Texas plant and a sudden drop in chlorine demand force chemical giant Olin Corp. to drastically cut its Q4 earnings forecast.

Kim Neville’s return from an in-house VP role signals a strategic play in Utah’s hot legal market and highlights a growing industry talent trend.

Azafaros presents its promising drug, nizubaglustat, for untreatable rare neurological disorders, backed by major funding and late-stage clinical trials.

As legacy brand Hamilton Beach heads to a major conference, its high-stakes pivot from kitchen gadgets to health tech will be under the microscope.

Evergy is repurchasing $244M of its convertible notes, a strategic play to reduce future stock dilution and manage complex arbitrage market ripples.

Online education giant Stride, Inc. is embroiled in a legal battle over claims of inflated enrollment, systemic failures, and a 54% stock crash.

Keysight Technologies taps Applied Materials veteran Liz Morali to lead investor relations, a strategic move to bolster market confidence and articulate its complex growth story.

The planned exit of a key technology leader sends ripples through Photronics, raising questions about its innovation roadmap despite record financial success.

Occidental nets $9.7B from its OxyChem sale to Berkshire Hathaway, pivoting to oil and carbon capture while retaining significant environmental liabilities.

SPAR Group appoints a CPG veteran to lead North American sales while top executives make significant share purchases, signaling strong internal confidence.

Investors eye Hexcel's Q4 2025 results for signs of an aerospace rebound, strategic shifts under new leadership, and the future of advanced composites.

RPM International's 52nd straight year of dividend hikes cements its 'Dividend King' status. We look at the strategy behind this rare achievement.